Evidence map›Paper›PMID 42072470›Full record

ArticleBiomedicines2026

IGF2BP2 Overexpression Predicts Poor Prognosis and Correlates with PD-L1 Expression in Intrahepatic Cholangiocarcinoma.

Jianan Shen, Aihua Yang, Xintao He, Tianyi Dai, Zexuan Hui, Youxiang Ding, Li Zhao, Jun Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jianan ShenDepartment of Pathology, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210000, China.ORCID 0009-0006-0206-2020
Aihua YangDepartment of Pathology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210000, China.
Xintao HeDepartment of Pathology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210000, China.ORCID 0009-0007-5140-4872
Tianyi DaiDepartment of Pathology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210000, China.
Zexuan HuiDepartment of Pathology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210000, China.
Youxiang DingDepartment of Pathology, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210000, China.
Li ZhaoPublic Experimental Platform, China Pharmaceutical University, Nanjing 211198, China.
Jun ChenDepartment of Pathology, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210000, China.ORCID 0000-0003-3905-4615

Funding

Nanjing Drum Tower Hospital 2022LCYJ-MS27Nanjing Health and Health Commission ZDX22001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

IGF2BP2immune checkpointintrahepatic cholangiocarcinomaprognosistumor microenvironment

Identifiers

PMID42072470
PMCPMC13113562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.